ecTMB: a robust method to estimate and classify tumor mutational burden

Area of Science:

• Oncology
• Genomics
• Biomarker Discovery

Background:

• Tumor Mutational Burden (TMB) is a key biomarker for anti-PD-(L)1 therapy and prognosis.
• Current TMB assays face challenges in consistency and meaningful threshold definition.
• These limitations hinder the clinical adoption of TMB as a reliable biomarker.

Purpose of the Study:

• To introduce ecTMB, a novel method for robust TMB estimation and classification.
• To address the inconsistencies in TMB measurement across different assays.
• To define biologically meaningful subtypes based on TMB for improved clinical utility.

Main Methods:

• Development of ecTMB, incorporating an explicit background mutation model.
• Robust prediction of TMB using the ecTMB methodology.
• Classification of tumor samples into subtypes based on predicted TMB values.

Main Results:

• ecTMB demonstrates robust prediction of Tumor Mutational Burden.
• The method enables reliable classification of samples into TMB-defined subtypes.
• This approach aims to overcome current limitations in TMB assay standardization.

Conclusions:

• ecTMB offers a standardized and robust approach to TMB assessment.
• The method facilitates the classification of tumors into biologically relevant subtypes.
• This advancement is expected to enhance the utility of TMB as a clinical biomarker.